Get the Stockscreener App
10.83
1.48%
0.325
Rallybio Corp stock is traded at $10.83, with a volume of 178.40K.
It is up +1.48% in the last 24 hours and up +129.19% over the past month.
Rallybio Corp is a clinical-stage biotechnology company engaged in the development of therapeutic candidates for severe and rare diseases. It focuses on the treatment of conditions related to complement dysregulation and hematologic disorders. The company's flagship program, RLYB116, is a C5 inhibitor being evaluated for potential use in diseases associated with complement dysregulation, including immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody candidate under investigation for the treatment of iron overload disorders.
See More
Previous Close:
$10.51
Open:
$10.49
24h Volume:
178.40K
Relative Volume:
1.77
Market Cap:
$57.45M
Revenue:
-
Net Income/Loss:
$-74.56M
P/E Ratio:
-5.9129
EPS:
-1.8316
Net Cash Flow:
$-60.27M
1W Performance:
+56.76%
1M Performance:
+129.19%
6M Performance:
+118.95%
1Y Performance:
+91.45%
1-Day Range:
$10.35
$10.89
1-Week Range:
$6.66
$11.49
52-Week Range:
$1.7608
$11.49
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
10.88 | 55.47M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
$105M for Starface pimple patches, humanoid robot maker eyes €1B and Rallybio's reverse merger - Axios
Candid Therapeutics to Merge with Rallybio in Reverse Merger - themiddlemarket.com
Rallybio Investor Alert: Merger Investigation Launched - National Today
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio CorporationRLYB - The AI Journal
Candid lists via Rallybio reverse merger, adds $505m financing - The Pharma Letter
Candid Therapeutics: $505 Million Financing And Merger With Rallybio To Advance Autoimmune T-Cell Engager Pipeline - Pulse 2.0
TPG group shows 7.2% Rallybio (RLYB) stake and supports Candid merger - Stock Titan
RLYB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rallybio merger deal includes $50M breakup fee, $200M financing floor - Hartford Business Journal
Rallybio to acquire Candid Therapeutics - Yahoo Finance
Latham & Watkins Advises on US$505 Million Financing in Connection With Rallybio-Candid Therapeutics Merger - Legal Desire Media and Insights
Rallybio, Candid Therapeutics announce merger agreement - TipRanks
Firm Advises Candid Therapeutics on Patent Matters Related to Acquisition by Rallybio - Wilson Sonsini
Rallybio and Candid Therapeutics To Merge - citybiz
Candid, in a reverse merger with RallyBio, to go public - BioPharma Dive
Rallybio to acquire Candid Therapeutics in $505M deal - Investing.com
Candid Therapeutics Strikes Up Merger With Rallybio to Advance Its Autoimmune Drug Pipeline - MedCity News
Rallybio: Merger forms a TCE therapeutics leader with $500M+ capital to advance autoimmune disease pipeline - TradingView
Rallybio: Merger forms a top TCE therapeutics company with $700M cash, advancing a broad autoimmune pipeline - TradingView
Candid scores Nasdaq listing via reverse merger Rallybio - Fierce Biotech
Rallybio to merge with San Diego biotech in deal backed by $505M in financing - Hartford Business Journal
Rallybio to Merge with Candid Therapeutics in All-Stock Deal - TipRanks
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Deal for its Shareholders - The AI Journal
Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Benzinga
Rallybio Corporation (NASDAQ:RLYB) Given Average Recommendation of "Reduce" by Brokerages - MarketBeat
Merger: Rallybio (RLYB) to combine with Candid with $505.5M concurrent financing - Stock Titan
Rallybio to Merge With Candid Therapeutics; Candid Holders to Own ~57.6% of Combined Company - TradingView
Candid Therapeutics, Rallybio (NASDAQ: RLYB) in $505M cash-backed merger - Stock Titan
Candid to go public via reverse merger with Rallybio - Endpoints News
Nvidia and Coherent announce a strategic partnership to jointly develop advanced optical technologies, aiming to drive the scaled development of next-generation data center architectures. - Bitget
Rallybio Corporation and Candid Therapeutics announce merger agreement - marketscreener.com
Rallybio Corporation And Candid Therapeutics Announce Merger Agreement - TradingView
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
RLYB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
5AM Ventures revises Rallybio (RLYB) ownership and discloses stock sales - Stock Titan
Rallybio’s RLYB116 Clears Phase 1 Milestone, Sharpening Its Autoimmune Pipeline - TipRanks
RLYB PE Ratio & Valuation, Is RLYB Overvalued - Intellectia AI
Rallybio's Strategic Pivot: Clinical Milestones and Financial Runway in Focus - AD HOC NEWS
Rallybio (RLYB) Price Target Increased by 700.00% to 8.16 - Nasdaq
Lieber, Rallybio CFO, sells $3992 in shares By Investing.com - Investing.com Canada
Lieber, Rallybio CFO, sells $3992 in shares - Investing.com
Rallybio (RLYB) CFO gets 2,500-share award, sells 789 shares for taxes - Stock Titan
Rallybio (NASDAQ: RLYB) director granted options in lieu of cash - Stock Titan
What is Rallybio Corporation’s valuation compared to sector2025 Market Trends & Daily Volume Surge Signals - mfd.ru
Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - Cision News
Rallybio reports positive phase 1 results for subcutaneous C5 inhibitor By Investing.com - Investing.com Canada
Rallybio reports positive phase 1 results for subcutaneous C5 inhibitor - Investing.com Australia
Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement - BioSpace
Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga
Rallybio announces positive data for RLYB116 phase 1 study - marketscreener.com
Weekly Rallybio shot fully shuts down terminal complement in early trial - Stock Titan
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):